The latest price target for Pacira BioSciences (NASDAQ:PCRX) was reported by RBC Capital on May 1, 2026. The analyst firm set a price target for $24.00 expecting PCRX to rise to within 12 months (a possible 3.40% upside). 8 analyst firms have reported ratings in the last year.

The latest analyst rating for Pacira BioSciences (NASDAQ:PCRX) was provided by RBC Capital, and Pacira BioSciences maintained their sector perform rating.

The last upgrade for Pacira BioSciences Inc happened on January 30, 2025 when Truist Securities raised their price target to $25. Truist Securities previously had a sell for Pacira BioSciences Inc.

The last downgrade for Pacira BioSciences Inc happened on August 13, 2024 when Truist Securities changed their price target from $30 to $8 for Pacira BioSciences Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Pacira BioSciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Pacira BioSciences was filed on May 1, 2026 so you should expect the next rating to be made available sometime around May 1, 2027.

While ratings are subjective and will change, the latest Pacira BioSciences (PCRX) rating was a maintained with a price target of $22.00 to $24.00. The current price Pacira BioSciences (PCRX) is trading at is $23.21, which is within the analyst’s predicted range.